HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
TUESDAY, June 7, 2022 (HealthDay News) -- For youth with type 2 diabetes, dulaglutide is superior to placebo for reducing mean glycated hemoglobin level, according to a study published online June 4 in the New England Journal of Medicine to coincide with the annual meeting of the American Diabetes Association, held from June 3 to 7 in New Orleans.
Silva A. Arslanian, M.D., from the University of Pittsburgh School of Medicine, and colleagues conducted a double-blind, placebo-controlled 26-week trial involving 154 participants (aged 10 to <18 years; body mass index [BMI] >85th percentile) being treated with lifestyle modifications alone or with metformin with or without basal insulin who were randomly assigned to receive once-weekly subcutaneous injections of placebo, dulaglutide 0.75 mg, or dulaglutide 1.5 mg. Participants were then included in a 26-week open-label extension, and those who had received placebo were switched to dulaglutide 0.75 mg.
The researchers found that at 26 weeks, the mean glycated hemoglobin level increased in the placebo group (0.6 percentage points) and decreased in the dulaglutide groups (−0.6 and −0.9 percentage points in the 0.75-mg and 1.5-mg groups, respectively). A higher percentage of participants in the pooled dulaglutide groups had a glycated hemoglobin level of less than 7.0 percent than in the placebo group at 26 weeks (51 versus 14 percent). In the placebo group, fasting glucose concentration increased (17.1 mg/dL), while in the pooled dulaglutide groups, there was a decrease (−18.9 mg/dL); no between-group differences were seen in the change in BMI.
"Among youths with inadequately controlled type 2 diabetes being treated with or without metformin or basal insulin, once-weekly treatment with dulaglutide was superior to placebo in improving glycemic control," the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including Eli Lilly, which manufactures dulaglutide and funded the study.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Published on June 07, 2022